FilingSEC EDGAR6-K
Can-Fite BioPharma Reports Clinical Improvement in Cirrhosis Patient with Namodenoson
· SEC accepted
StageClinical case report
Filing content
Can-Fite BioPharma published a case report of a patient with advanced decompensated cirrhosis who showed clinical improvement and successful bridging to liver transplantation after Namodenoson treatment.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…